We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...

Viking Therapeutics Inc’s profitability metrics reveal financial health. The company currently boasts a gross margin of -34.83%. The profit margin, also known as the revenue ratio or gross profit ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the ...

Viking today announced the Explorers’ Sale, providing North American travelers with new booking incentives across the company’s extensive range of river, ocean and expedition voyages.

Viking® ( (NYSE: VIK) today announced the Explorers’ Sale, providing North American travelers with new booking incentives across the company’s extensive range of river, ocean and expedition voyages.

Viking Therapeutics (VKTX) has received a new Buy rating, initiated by Stifel Nicolaus analyst, Annabel Samimy.Stay Ahead of the ...

providing North American travelers with new booking incentives across the company’s extensive range of river, ocean and expedition voyages. From now through January 31, 2025, Viking is offering ...

Palantir Technologies (NASDAQ:PLTR) has been described as the best pure-play stock in artificial intelligence. The market ...

Lessons in Creativity and Innovation from the Notes of Brilliant Thinkers by Jillian Hess, a professor of English at the City ...

JPMorgan highlights valuation resets for Viking and Structure Therapeutics, citing opportunities in T2D/obesity and competitive clinical data insights.

Viking Therapeutics Inc (VKTX) stock saw a decline, ending the day at $38.88 which represents a decrease of $-0.43 or -1.09% from the prior close of $39.31. The stock opened at $38.25 and touched a ...